Posts by charly


    "Fazit: Mit dem Kauf eines ETF auf einen Index am Anfang der Liste kann man sehr gut schlafen,..."


    ... wieso ETF wo der Emittent die Dividenden einsackt und erst noch bescheisst mit hohem Spread?

    Da kann man doch besser die SMI-Schwergewichte Novartis, Roche und Nestlé ins Depot legen und zum Bsp. Verizon/USD die zahlen hohe Dividende mit geringen Kursschwankungen.…

    Commencement of the 2021 Work Programme – Beetaloo Sub-Basin
    Falcon Oil & Gas Ltd.
    Commencement of the 2021 Work Programme – Beetaloo Sub-Basin

    22 June 2021 – Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) is pleased to announce the commencement of the 2021 work programme, starting with operations at Kyalla 117 N2-1H ST2 (“Kyalla 117”) in the Beetaloo Sub-Basin, Northern Territory, Australia with our joint venture partner, Origin Energy B2 Pty Ltd, a wholly owned subsidiary of Origin Energy Limited (“Origin”).
    On-site operations at Kyalla 117 have begun, with rigging up now complete, and clean-up operations resumed. These operations, if successful, will result in an extended production test (“EPT”) being carried out to determine the expected longer-term performance of the well.
    Further details on the 2021 work programme, including proposed activity at Velkerri 76 and Amungee NW 1H, are set out below.

    Kyalla 117
    Kyalla Shale Play Summary
    Liquids rich gas play, which has only been identified in the joint venture acreage.
    Material play fairway > 3,000 km2 with multi TCF potential.
    Liquids rich play with two prospective stacked targets in the gas window, and one in the oil window.

    Results to date
    As announced on 19 January 2021, Origin submitted a notification of discovery and an initial report of discovery to the Northern Territory Government.
    Unassisted gas flow rates ranging between 0.4-0.6 MMscf/d were recorded over seventeen hours, which are preliminary indications of well performance, and an EPT is required to determine the longer-term performance of Kyalla 117.

    Velkerri Shale Play Summary
    Largest play fairway in the Beetaloo with four prospective stacked targets.
    Predominantly dry gas with OGIP > 500+ TCF.
    Liquids rich gas fairways on basin flanks with multi TCF potential.
    Multiple successful tests within the dry gas window (Amungee NW 1H, Tanumbrini1, Shenandoah 1A).
    2021 work programme includes:
    Targeting the Velkerri play along the south-eastern flank of the Beetaloo Sub-Basin, which is predicted to be in a liquids rich gas window.
    Drill a vertical pilot well to acquire core, run logs and perform diagnostic fracture injection test data across the Velkerri.

    Results to date
    On 22 December 2016 Falcon announced that, following a 57-day EPT of the well, production averaged 1.10 MMscf/d.
    On 15 February 2017 Falcon announced that Origin had submitted the Results of Evaluation of the Discovery and Preliminary Estimate of Petroleum in Place for the Amungee NW-1H Velkerri B Shale Gas Pool to the Northern Territory Government amounting to a gross contingent resource of 6.6 TCF, 1.46 TCF net to Falcon.

    2021 work programme includes:
    An extended production test and production log to confirm zonal contribution, i.e. determine if all frack stages contributed to the initial EPT conducted in 2016.

    Philip O’Quigley (CEO of Falcon) commented:
    “The commencement of operations at Kyalla 117 is an exciting first step for the planned 2021 work programme which will cover three different plays in the Beetaloo providing key information that will help determine the future appraisal and development programme. We look forward to providing results as soon as they become available.”

    I offer the reason why CoviSTIX approval has taking so "long" is because the FDA has asked Sorrento to create a reporting/tracking system so that it can be used as an official record. Big Brother issues aside, they must be so confident in the accuracy that they have asked (read: given Sorrento additional funding and/or other commercial enticement) to create a test report bona fide product.

    External Content
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

    Up we go

    MIMEDX Receives Regulatory Approval To Commercialize EPIFIX® In Japan

    June 8, 2021 at 8:30 AM EDT

    Availability of EPIFIX Allografts Expected Early 2022

    Approval Makes it Possible to Bring EPIFIX’s Healing Properties to as Many as 100,000 New Patients Annually

    MARIETTA, Ga., June 08, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced successful regulatory approval by the Japanese Ministry of Health, Labour and Welfare (JMHLW) to market EPIFIX® in Japan.

    EPIFIX - a bioabsorbable, human amniotic membrane allograft, is applied to affected areas for wound healing. The product uses proprietary methods, including the PURION® process, to provide a semi-permeable, protective barrier that supports the healing cascade. EPIFIX protects the wound bed to aid in the development of granulation tissue and delivers a human biocompatible extracellular matrix that retains 300+ regulatory proteins.

    MIMEDX submitted a Shonin (pre-market approval) to the JMHLW, Japan’s primary regulatory body for creating and implementing safety standards for drugs and medical devices, and the Pharmaceutical and Medical Device Agency (PMDA), an independent administrative agency that works with JMHLW to ensure the safety and quality of drugs and medical devices, in mid-2020. EPIFIX was approved for hard-to-heal chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs), which do not respond to conventional therapy. EPIFIX will be classified as a Class IV Medical Device and “Specified Biological Product” under JMHLW guidelines.

    Dr. Hiroto Terashi, Chief Professor in Department of Plastic Surgery at Kobe University, Chairman of the Japanese Society for Foot Care and Podiatric Medicine (JFCPM), and Chairman of the Japan Society for Surgical Wound Care (JSSWC) said, “As a plastic surgeon and wound care physician for my entire career, I am delighted with EPIFIX’s approval in Japan. EPIFIX will greatly expand treatment options for chronic wounds caused by lower extremity venous and diabetic ulcers in patients in Japan, providing opportunities for increased limb salvage.”

    "Diabetic foot ulcers and venous leg ulcers that are unable to heal on their own pose a serious long-term health risk to people around the world. Our vision is to provide access to EPIFIX technology that can change people’s lives, no matter where they live,” said Stan Micek, MIMEDX Senior Vice President, Business Development and International. “We are extremely pleased with JMHLW’s decision to grant Shonin approval for EPIFIX, and we are glad to be one step closer to bringing EPIFIX to market in Japan. Our focus will now shift toward obtaining appropriate reimbursement and establishing logistical and distribution networks for commercialization, which we hope will result in full availability of EPIFIX in the Japanese market in early 2022.”

    The Company is currently working with JMHLW to establish reimbursement pricing, a process expected to take up to six months. Once a reimbursement pricing policy is approved and the reimbursement rate is listed, the Company can begin offering EPIFIX to patients and providers in Japan.

    Timothy R. Wright, MIMEDX Chief Executive Officer, commented, “EPIFIX can only benefit patients with hard-to-heal wounds if they can access its life-improving properties, and regulatory approval is a significant milestone in addressing unmet need for people in Japan. With today’s announcement, EPIFIX now has the potential to reach as many as 100,000 additional patients each year. This critical step helps us fulfil our mission of bringing advanced regenerative medicine to suffering patient populations and is important in the Company’s global expansion.”

    Important Cautionary Statement

    This press release includes forward-looking statements, including among other things, statements regarding: (i) expectations about the classification of EPIFIX as a Class IV Medical Device and “Specified Biological Product” under JMHLW guidelines; (ii) expectation that EPIFIX will greatly expand treatment options for chronic wounds caused by lower extremity venous and diabetic ulcers in patients in Japan; and (iii) the Company’s expectations regarding the approval of a reimbursement pricing policy for EPIFIX in Japan and the timeline for availability of EPIFIX in the Japanese market. Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations.

    Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) the Company may change its plans due to unforeseen circumstances, and delay or alter the timeline for future trials, analyses, or public announcements; (ii) the timing of any meeting with or decision by JMHLW depends on many factors and the availability and timing of such a meeting or decision is outside of the Company’s control; and (iii) reimbursement pricing approval requires the satisfaction of various conditions; is often subject to detailed rules; and the timing, amount, and final approval decision rests with the JMHLW. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement


    Der geschätzte Bedarf an Systemen wird sich dann auf 50 bis 100 Systeme für die jährliche Produktion von neun Arzneimitteln belaufen. Unabhängig davon, wer die Technologie lizenziert.

    Der Preis wird ca 3 Millionen € für eine von GMC zugelassene Drapiermaschine betragen. Darüber hinaus gibt es Service und f-Material...

    Obducat kaufen!

    ABB: Goldman Sachs ist für BUY bis 39 (37.50) Fr. Begrüsst geplante Bereinigung des Firmenportfolios

    ...wenn das keine Ansage ist :)

    Kurs aktuell: Fr. 29.99